美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · NTRA近 30 天 21 則 · 第 1 / 1 頁
- Why Natera (NTRA) Is Up 12.3% After Landmark Lung Cancer MRD Data At IASLC 2026
- Natera (NTRA) Stock Fair Value Rises After Signatera And Guidance Drive Analyst Revisions
- Natera CEO Steven Chapman Sells 1,698 Shares for $545,000
- 肺癌最大規 R 究凸 ignateraT 強大預後價值Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
- Natera Stock Has Excellent Technical ‘DNA’ as NTRA Sets a New All-Time High
- When To Sell Stocks: Why Investors May Want To Walk Away From These IBD 50 Stocks
- 3 Reasons Investors Love Natera (NTRA)
- Jim Cramer Calls Natera (NTRA) “a Promising Story”
- New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
- 3 Momentum Stocks to Own for Decades
- Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?
- Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
- Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
- 3 Healthcare Stocks with Promising Prospects
- How Investors May Respond To Natera (NTRA) New MRD Trial Deal And Duquesne Stake Expansion
- Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
- Natera (NTRA) Supplies MRD Assay For Phase 1 Skin Cancer Immunotherapy Trial
- Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal
- VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
- What Is Really Moving Tempus AI Stock Right Now?
- Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.
- Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。